Ask Warren

Daewon Pharmaceutical

003220 · KOSPI · ₩003220 · 대원제약

₩7,700▼ ₩60 (0.77%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩153B₩158B₩160B₩144B₩144B₩158B₩145B₩157B
Cost of sales₩82B₩83B₩86B₩83B₩80B₩83B₩77B₩82B
Gross profit₩71B₩75B₩74B₩61B₩63B₩75B₩68B₩75B
Operating income−₩8.9M₩4.4B₩5.9B−₩10B−₩1.4B₩9.4B₩3.2B₩11B
Net income₩1.9B₩1.9B₩14B−₩15B−₩8.4B₩4.9B−₩3.3B₩5.6B
Net income to shareholders₩4B₩2.4B₩14B−₩17B−₩3B₩5.4B−₩1.1B₩6.8B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩573B₩596B₩614B₩606B₩581B₩599B₩583B₩599B
Current assets₩234B₩238B₩257B₩267B₩247B₩267B₩258B₩284B
Cash and equivalents₩24B₩28B₩47B₩20B₩13B₩15B₩17B₩16B
Total liabilities₩298B₩325B₩339B₩343B₩301B₩316B₩299B₩309B
Current liabilities₩208B₩201B₩216B₩223B₩206B₩219B₩201B₩209B
Borrowings₩184B₩181B₩198B₩209B₩176B₩101B₩153B₩155B
Total equity₩276B₩271B₩275B₩264B₩280B₩283B₩285B₩290B
Shareholders' equity₩268B₩263B₩266B₩256B₩272B₩274B₩275B₩279B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩4.4B₩9.2B₩31B−₩17B₩21B₩7.6B₩31B₩20B
Capital spending₩1.9B₩7.9B₩7.3B₩6.2B₩9.4B₩6.9B₩3B₩22B
Free cash flow−₩6.3B₩1.3B₩23B−₩23B₩12B₩637M₩28B−₩1.7B
Dividends paid₩0₩5.4B₩0₩0₩0₩6.4B₩0₩0

Consolidated where available. Amounts in won.

Also known as: Daewon Pharmaceutical / 대원제약 / 003220 / KRX:003220

Source: KRX statistical information